Epigallocatechin

Epigallocatechin

SCHEMBL29929503

Oc1cc(O)c2c(c1)OC(c1cc(O)c(O)c(O)c1)C(O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 6/20 1.00
KDM4E B2RXH2 6/20 1.00
PTGS1 P23219 5/20 1.00
SNCA P37840 4/20 1.00
MAPT P10636 4/20 1.00
APEX1 P27695 4/20 1.00
RECQL P46063 4/20 1.00
HSD17B10 Q99714 4/20 1.00
ALDH1A1 P00352 3/20 1.00
HPGD P15428 3/20 1.00
ALOX15 P16050 3/20 1.00
TDP1 Q9NUW8 3/20 1.00
RAD52 P43351 2/20 1.00
CNR1 P21554 1/20 1.00
MEN1 O00255 4/20 0.74
KMT2A Q03164 4/20 0.74
GAA P10253 3/20 0.74
CYP3A4 P08684 3/20 0.74
PKM P14618 2/20 0.74
PTGS2 P35354 2/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epigallocatechin SCHEMBL29870730 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL12840936 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL1972940 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
(-)-Gallocatechin SCHEMBL30159803 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL1972938 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL12285364 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL19553 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Gallocatechin SCHEMBL3872234 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
Epigallocatechin SCHEMBL20203645 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT
(-)-Gallocatechin SCHEMBL1742127 1.00 BACE1 (1.00) BACE1KDM4EPTGS1SNCAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO disclosed
EP-4117455-A2 NOVEL NUTRIENTS TO ENHANCE LOAD-INDUCED MUSCLE HYPERTROPHY The Regents of the University of California (US) 2023-01-18 EP disclosed
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof RAYZEBIO, INC. (US) 2022-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11497822-B1 Stabilized compositions of radionuclides and uses thereof TFRC, SLC39A14, EGFR BACE1 1741/4885KDM4E 3658/4885PTGS1 4873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.